• 1
    Badizadegan K, Jonas MM, Ott MJ, Nelson SP, Perez-Atayde AR. Histopathology of the liver in children with chronic hepatitis C viral infection. HEPATOLOGY 1998; 28: 14161423.
  • 2
    Bortolotti F, Jara P, Diaz C, Vajro P, Hierro L, Giacchino R, et al. Posttransfusion and community-acquired hepatitis C in childhood. J Pediatr Gastroenterol Nutr 1994; 18: 279283.
  • 3
    Matsuoka S, Tatara K, Hayabuchi Y, Taguchi Y, Mori K, Honda H, et al. Serologic, virologic, and histologic characteristics of chronic phase hepatitis C virus disease in children infected by transfusion. Pediatrics 1994; 94: 919922.
  • 4
    Strickland DK, Jenkins JJ, Hudson MM. Hepatitis C infection and hepatocellular carcinoma after treatment of childhood cancer. J Pediatr Hematol Oncol. 2001; 23: 527529.
  • 5
    Davis GL. Treatment of acute and chronic hepatitis C. Clin Liver Dis 1997; 1: 615630.
  • 6
    Jacobson KR, Murray K, Zellos A, Schwarz KB. An analysis of published studies of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 34: 5258.
  • 7
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 14851492.
  • 8
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised study of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 14261432.
  • 9
    Ruiz-Moreno M, Rua MJ, Castillo I, Garcia-Novo MD, Santos M, Navas S, et al. Treatment of children with chronic hepatitis C with recombinant interferon-α: a pilot study. HEPATOLOGY 1992; 16: 882885.
  • 10
    Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. HEPATOLOGY 1997; 26: 16401645.
  • 11
    Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74(Pt 6): 10931102.
  • 12
    Holland J, Bastian I, Ratcliff RM, Beers MY, Hahesy P, Harley H, et al. Hepatitis C genotyping by direct sequencing of the product from the Roche Amplicore test: methodology and application to a south Australian population. Pathology 1998; 30: 192195.
  • 13
    Doglio A, Laffont C, Thyss S, Lefebvre JC. Rapid genotyping of hepatitis C virus by direct cycle sequencing of PCR-amplified cDNAs and capillary electrophoresis analysis. Res Virol 1998; 149: 219227.
  • 14
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207214.
  • 15
    Obenauer-Kutner L, Jacobs SJ, Kolz K, Tobias LM, Bordens RW. A highly sensitive electrochemiluminescence immunoassay for interferon alfa-2b in human serum. J Immunol Methods 1997; 206: 2533.
  • 16
    Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998; 46: 563570.
  • 17
    National Center for Health Statistics. National Health and Nutrition Examination Survey: 2000 CDC Growth Charts: United States. Last update: 2002. Available at:
  • 18
    Christensson B, Wiebe T, Akesson A, Widell A. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 2000; 30: 585586.
  • 19
    Lackner H, Moser A, Deutsch J, Kessler HH, Benesch M, Kerbl R, et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000; 106: E53.
  • 20
    Suoglu OD, Elkabes B, Sokucu S, Saner G. Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C? J Pediatr Gastroenterol Nutr 2002; 34: 199206.
  • 21
    Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. HEPATOLOGY 2002; 36: 12801284.
  • 22
    McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000; 119: 13171323.
  • 23
    Iorio R, Pensati P, Botta S, Moschella S, Impagliazzo N, Vajro P, et al. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 1997; 16: 984990.
  • 24
    Centers for Disease Control and Prevention. Youth risk behavior surveillance—United States 2001. CDC Morb Mortal Wkly Rep 2001; 51(SS04): 164.
  • 25
    Druss B, Pincus H. Suicidal ideation and suicide attempts in general medical illnesses. Arch Intern Med 2000; 160: 15221526.
  • 26
    González-Peralta RP, Glue P, Hodik M, Davis GL, Lau JYN. Single-dose pharmacokinetics of interferon alfa2b in children with chronic hepatitis C [Abstract]. HEPATOLOGY 1999; 30: 264A.